Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Steam-In-Place (SIP) Procedures – V 2.0

Posted on By


Biosimilars: SOP for Steam-In-Place (SIP) Procedures – V 2.0


Standard Operating Procedure for Steam-In-Place (SIP) Procedures in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/126/2025
Supersedes SOP/BS/126/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a validated and standardized procedure for executing Steam-In-Place (SIP) of bioreactors, media transfer lines, and associated components used in biosimilar manufacturing to ensure sterility before use.

2. Scope

This SOP applies to all stainless steel and single-use bioreactor systems, piping, filters, and vessels requiring SIP before aseptic processing in biosimilar upstream and downstream operations.

3. Responsibilities

  • Production Staff: Initiate, monitor, and document the SIP process.
  • Engineering: Maintain SIP systems, calibrate instruments, and support troubleshooting.
  • QA: Review SIP cycle records and approve sterilization results before batch initiation.

4. Accountability

The Manufacturing Head is accountable for ensuring compliance with validated SIP procedures and that no equipment is used without a completed and approved SIP cycle.

5. Procedure

5.1 Pre-SIP Checks

  1. Ensure equipment is cleaned as per CIP SOP and logged.
  2. Confirm:
    • Steam generator is functional
    • Drain and air vent lines are open
    • Temperature and pressure sensors are calibrated
  3. Record equipment ID, date, and initials in Annexure-1: SIP Preparation Checklist.

5.2 SIP Execution Parameters

  1. Use validated SIP cycle:
    • Temperature: ≥121°C
    • Hold Time: Minimum 30 minutes
    • Steam Pressure: 1.0–1.5 bar
  2. Start the SIP cycle using the control system or manual valve sequencing.
  3. Monitor temperature at:
    • Top of vessel
    • Outlet point
    • Cold spots (as identified in qualification)

5.3 Post-SIP Procedure

  1. Close all valves and isolate sterile lines using sterile caps or PTFE tape.
  2. Allow equipment to cool to ambient under filtered air.
  3. Visually inspect for condensate or water pooling.
  4. Record SIP cycle printout and temperature graphs.
  5. Fill Annexure-2: SIP Execution Record.

5.4 Verification and Release

  1. QA to review SIP records and verify temperature profiles meet specifications.
  2. Apply “SIP Completed” status tag and authorize for use.

5.5 Deviations and Failures

  1. If cycle aborts or temperature drops below target:
    • Label equipment as “NOT STERILE – DO NOT USE”
    • Investigate root cause and document in Annexure-3
    • Repeat SIP only after clearance from Engineering and QA

6. Abbreviations

  • SIP: Steam-In-Place
  • CIP: Clean-In-Place
  • QA: Quality Assurance
  • PTFE: Polytetrafluoroethylene

7. Documents

  1. SIP Preparation Checklist – Annexure-1
  2. SIP Execution Record – Annexure-2
  3. SIP Deviation Log – Annexure-3

8. References

  • EU GMP Annex 1 – Manufacture of Sterile Medicinal Products
  • WHO TRS 1019 – GMP for Biotech Manufacturing
  • ISPE Baseline Guide: Sterile Manufacturing Facilities

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: SIP Preparation Checklist

Step Status Initials
Drain Open Yes AR
Steam Supply Verified Yes AR

Annexure-2: SIP Execution Record

Date Equipment ID Start Time Hold Temp Hold Time Verified By
04/05/2025 BR-100L 10:00 122.5°C 32 min Sunita Reddy

Annexure-3: SIP Deviation Log

Date Issue Root Cause Corrective Action Reviewed By
02/05/2025 Temp drop to 119°C Steam trap leak Trap replaced QA

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Cycle parameters revised and deviation procedure added Validation update
See also  Biosimilars: SOP for Temperature Control in Bioreactor Operations - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Creams: SOP for Ensuring Training Compliance for QA Personnel – V 2.0
Next Post: Analytical Method Development: SOP for GC-MS Method for Residual Solvents – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version